Is Sermorelin Legal in New York? How to Access It Legally

Print or save as PDF

Key numbers

  • 30 micrograms per kgStudy dose of sermorelin used in the pivotal pediatric program, once daily subcutaneously at bedtime; not a recommended doseSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
  • 14 daysDuration of the study in older men that used 0.5 mg or 1 mg sermorelin twice daily; a study dose, not a recommended doseSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
  • 0.05 mgGeref strength per ampule under NDA 019863, approved for testing the pituitary's growth hormone secretionSource: federalregister.gov, as cited Nov 7, 2026

See the public record for Sermorelin

  • FDA-approved today / No — Geref's approvals were withdrawn in 2009 [1]
  • Drug class / GHRH analogue; prompts the pituitary to release growth hormone [3]
  • What is sold now / Compounded, not FDA-approved [2]
  • FDA safety-risk bulk list / Sermorelin is not listed [4]
  • Outsourcing-facility nominations / Category 1, under evaluation [5]
  • State-pharmacy bulk list / Sermorelin appears in no category [6]
  • Sport / Prohibited at all times by WADA, S2.2.4 [7]

What is sermorelin's legal status today?

Sermorelin is a 29-amino-acid analogue of growth hormone-releasing hormone; it prompts the pituitary to release the body's own growth hormone and is not growth hormone itself [3]. Its effect is rapid and short-lived: after an intravenous dose in healthy men, sermorelin was eliminated quickly, yet growth hormone stayed raised for about three hours [8].

No sermorelin product is FDA-approved today. Geref was discontinued in 2008, and FDA withdrew its approvals effective June 18, 2009 [1]. What is sold now is compounded, and compounded drugs are not FDA-approved [2].

HealthRX.com offers sermorelin by prescription.

Questions worth asking

Choose the questions you want to keep

What happened to Geref?

Geref existed under two applications [1]: NDA 019863, 0.05 mg per ampule, approved December 28, 1990, for evaluating the pituitary's ability to secrete growth hormone; and NDA 020443, 0.5 mg and 1 mg vials, approved September 26, 1997, for treating idiopathic growth hormone deficiency in children with growth failure. The manufacturer discontinued both and asked FDA to withdraw them; in March 2013 FDA determined Geref was not withdrawn for reasons of safety or effectiveness [1][9]. Its approved uses were only that pediatric treatment and the diagnostic test — not adults, anti-aging, weight loss or athletic performance [1].

What do FDA's compounding lists say?

  • Safety-risk list: sermorelin is not among the bulk substances FDA has flagged as possibly presenting significant safety risks (content dated 04/22/2026) [4].
  • Outsourcing facilities: on the list updated March 21, 2025, sermorelin acetate is in category 1 (under evaluation) and carries the symbol for substances that are components of FDA-approved drugs [5].
  • State-licensed pharmacies and physicians: sermorelin appears in no category on the list updated May 14, 2026 [6], and it is not one of the six peptides in HHS's October 2026 draft enforcement-discretion policy [10].

Can athletes use it?

No — WADA's 2026 Prohibited List names sermorelin in S2.2.4, growth hormone releasing factors, alongside CJC-1293, CJC-1295 and tesamorelin, and prohibits it at all times, in and out of competition [7]. The 2027 List, in force January 1, 2027, also names it [11].

What doses have been studied?

No sermorelin product is currently FDA-approved, so there is no current FDA-approved dose. The pivotal pediatric program used 30 micrograms per kg once daily subcutaneously at bedtime, and a study in older men used 0.5 mg or 1 mg twice daily for 14 days; those are study doses, not recommended doses [12][13].

Is sermorelin legal in New York?
This page does not cover New York state law. Federally, no sermorelin product is FDA-approved today, and sermorelin sold in the US is compounded; FDA does not review compounded drugs for safety, effectiveness or quality before they are marketed [1][2]. Lack of FDA approval is not itself a ruling on state-level access.
Was sermorelin ever FDA-approved?
Yes, as Geref. A 0.05 mg diagnostic product was approved in 1990, and 0.5 mg and 1 mg vials in 1997 for idiopathic growth hormone deficiency in children; the maker discontinued it in 2008 and FDA withdrew both approvals in 2009 [1].
Is sermorelin banned in sport?
Yes. WADA's 2026 Prohibited List names sermorelin in S2.2.4 and prohibits it at all times, in and out of competition [7]. The 2027 List also names it [11].
Does FDA treat sermorelin as a compounding safety risk?
Sermorelin is not on FDA's list of bulk substances that may present significant safety risks, and it appears in no category on FDA's list for state-licensed pharmacies and physicians [4][6].
Show all 13 referencesHide references
  1. Federal Register :: Request Access.
  2. Official web page.
  3. Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2):139-57.
  4. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
  5. U.S. Food and Drug Administration.
  6. U.S. Food and Drug Administration.
  7. World Anti-Doping Agency.
  8. Wilton P, Chardet Y, Danielson K, Widlund L, Gunnarsson R. Pharmacokinetics of growth hormone-releasing hormone(1-29)-NH2 and stimulation of growth hormone secretion in healthy subjects after intravenous or intranasal administration. Acta Paediatr Suppl. 1993;388:10-5.
  9. U.S. Food and Drug Administration.
  10. Official web page.
  11. World Anti-Doping Agency.
  12. Thorner M, Rochiccioli P, Colle M, Lanes R, Grunt J, Galazka A, et al. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group. J Clin Endocrinol Metab. 1996;81(3):1189-96.
  13. Corpas E, Harman SM, Piñeyro MA, Roberson R, Blackman MR. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. J Clin Endocrinol Metab. 1992;75(2):530-5.
Sermorelin legal New York: evidence summary chart
Image: HealthRX.com. Full sermorelin legal New York guide and sources at healthrx.com/peptide-legal-sermorelin.